Ten63 Therapeutics
Melissa brings a track record of successfully defending intellectual property portfolios for biopharma and financial services firms, both large and small. She successfully defended her client in the largest securities litigation in history. She has played key roles in multiple M&A transactions including with Fortune 50 and other leading global firms. She previously served as Head of Digital Medicines and Senior VP at Novartis AG and as VP of Global Technology at Barclays Capital.
This person is not in any teams
This person is not in any offices
Ten63 Therapeutics
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the world’s most lethal diseases.